FMR LLC disclosed a 1.4% ownership stake in Tenax Therapeutics Inc. through a recent SEC Schedule 13G/A filing.
Tenax Therapeutics is a development-stage pharmaceutical company currently in Phase 3 of clinical development. The firm focuses on the creation of novel cardiopulmonary therapies.
President and CEO Chris Giordano is scheduled to present at the Cantor Global Healthcare Conference on September 9, 2026.